NewLink Genetics Corp (NASDAQ:NLNK) shares traded down 12.8% during trading on Friday . The company traded as low as $7.56 and last traded at $6.60. 812,550 shares traded hands during mid-day trading, an increase of 0% from the average session volume of 810,681 shares. The stock had previously closed at $7.57.

A number of research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a report on Wednesday, January 3rd. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Jefferies Group cut their price target on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus upped their price target on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics and gave the stock a “buy” rating in a report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $23.29.

The company has a market cap of $221.91, a price-to-earnings ratio of -2.79 and a beta of 1.15.

Institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC bought a new position in NewLink Genetics during the 3rd quarter worth about $4,581,000. Northern Trust Corp grew its holdings in NewLink Genetics by 4.0% during the 2nd quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after acquiring an additional 11,532 shares in the last quarter. Neuberger Berman Group LLC bought a new position in NewLink Genetics during the 3rd quarter worth about $305,000. Tudor Investment Corp ET AL bought a new position in NewLink Genetics during the 2nd quarter worth about $286,000. Finally, Stifel Financial Corp bought a new position in NewLink Genetics during the 3rd quarter worth about $402,000. Institutional investors own 52.68% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “NewLink Genetics (NLNK) Shares Down 12.8%” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2018/02/11/newlink-genetics-nlnk-shares-down-12-8.html.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.